Pulmonary Cryptococcosis After Initiation of Anti-Tumor Necrosis Factor-α Therapy

This publication has 7 references indexed in Scilit:

• Histoplasmosis after Treatment with Anti–Tumor Necrosis Factor-α Therapy
  American Journal of Respiratory and Critical Care Medicine, 2003
• Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management
  The Lancet Infectious Diseases, 2003
• Effects of Tumor Necrosis Factor Alpha on Dendritic Cell Accumulation in Lymph Nodes Draining the Immunization Site and the Impact on the Anticryptococcal Cell-Mediated Immune Response
  Infection and Immunity, 2003
• Induction of Interleukin-12 and Gamma Interferon Requires Tumor Necrosis Factor Alpha for Protective T1-Cell-Mediated Immunity to PulmonaryCryptococcus neoformansInfection
  Infection and Immunity, 2002
• Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing Agent
  New England Journal of Medicine, 2001
• Role of TNF-α in the Induction of Fungicidal Activity of Mouse Peritoneal Exudate Cells againstCryptococcus neoformansby IL-12 and IL-18
  Cellular Immunology, 1999
• The Evolution of Pulmonary Cryptococcosis
  Annals of Internal Medicine, 1981